Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

Keyphrases

• Kidney 100%
• Chronic Kidney Disease 100%
• Empagliflozin 100%
• Primary Kidney Disease 100%
• Kidney Disease Progression 57%
• Relative Effect 42%
• Estimated Glomerular Filtration Rate Slope 42%
• Estimated Glomerular Filtration Rate 28%
• Kidney Failure 28%
• Estimated Glomerular Filtration Rate Decline 28%
• Glomerular Disease 28%
• Italy 14%
• Risk Reduction 14%
• Albumin-to-creatinine Ratio 14%
• Germany 14%
• Diabetes 14%
• China 14%
• Japan 14%
• Placebo 14%
• Hazard Ratio 14%
• Interaction Terms 14%
• Canada 14%
• Medical Research Council 14%
• Slope Analysis 14%
• Standard of Care 14%
• Cox Model 14%
• Between-group Difference 14%
• Non-diabetic 14%
• Group Comparison 14%
• Phase II Trial 14%
• Subgrouping 14%
• Diabetic Kidney Disease 14%
• Once-daily 14%
• Composite Outcome 14%
• Hypertensive Disorders 14%
• Unknown Cause 14%
• Malaysia 14%
• Cardiovascular Mortality 14%
• End-stage Kidney Disease 14%
• Renovascular Disease 14%
• Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i) 14%
• Eli Lilly 14%
• Placebo Groups 14%
• Risk of Progression 14%
• Shared Parameter Model 14%

Medicine and Dentistry

• Nephropathy 100%
• Chronic Kidney Disease 100%
• Empagliflozin 100%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 100%
• Glomerular Filtration Rate 77%
• Effect Size 22%
• Renal Failure 22%
• Glomerulopathy 22%
• Placebo 22%
• Cardiovascular System 11%
• Creatinine 11%
• Albumin 11%
• Urinary System 11%
• Diabetes 11%
• Medical Research 11%
• Hazard Ratio 11%
• Diabetes Mellitus 11%
• Proportional Hazards Model 11%
• End Stage Renal Disease 11%
• Diabetic Nephropathy 11%
• Renovascular Disease 11%
• Sodium Glucose Cotransporter 2 Inhibitor 11%
• Kidney Disorder 11%
• Oral 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Kidney Disease 100%
• Chronic Kidney Failure 100%
• Empagliflozin 100%
• N Ethyl 2 [N (6 Methoxy 3 Pyridinyl) 2 Methylbenzenesulfonamido] N (3 Pyridinylmethyl)acetamide 100%
• Disease Exacerbation 40%
• Placebo 20%
• Kidney Failure 20%
• Glomerulopathy 20%
• Sodium Glucose Cotransporter 2 Inhibitor 10%
• End Stage Renal Disease 10%
• Creatinine 10%
• Renovascular Disease 10%
• Diabetes Mellitus 10%
• Diabetic Nephropathy 10%
• Albumin 10%